HealthDay News — Implantable cardioverter-defibrillators (ICDs) are effective in young patients with symptomatic Brugada syndrome, according to a study published in the Journal of the American College of Cardiology.
M. Cecilia Gonzalez Corcia, MD, from Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, and colleagues investigated clinical features, management, and long-term follow-up (mean, 88 months) of 35 young patients (mean age, 13.9 years) with Brugada syndrome who had an ICD implanted at an age of ≤20 years.
The researchers found that the vast majority of patients (92%) were symptomatic, including 29% presented with aborted sudden cardiac death and 63% with syncope. ICDs treated sustained ventricular arrhythmias in 9 patients, including shocks in 8 patients (23%) and antitachycardia pacing in 1 patient.
An electrical storm caused death in 3 patients, while 7 patients experienced inappropriate shocks and 5 patients had device-related complications. Independent predictors of appropriate shock occurrence were aborted sudden cardiac death and spontaneous type I electrocardiogram.
“ICD therapy is an effective strategy in young patients with symptomatic Brugada syndrome, treating potentially lethal arrhythmias in >25% of patients during follow-up,” the authors wrote.
Gonzalez Corcia MC, Sieira J, Pappaert G, et al. Implantable cardioverter-defibrillators in children and adolescents with Brugada syndrome. J Am Coll Cardiol. 2018;71(2):148-157.